Total Cost
Free shipping on all orders

Powered by GeniusRx

riluzole 50 mg tablet generic rilutek

In stock Manufacturer ASCEND LABORATO 67877028660
$3.24 / Tablet

Select Quantity

Prescription is required


Amyotrophic Lateral Sclerosis

Riluzole is used in the management of amyotrophic lateral sclerosis (ALS) and has been designated an orphan drug by the FDA for use in this condition.

ALS (i.e., Lou Gehrig disease, Charcot sclerosis) is a fatal, progressive neurodegenerative disease affecting both upper and lower motor neurons; manifestations include gradual weakness and atrophy in limb, thoracic, abdominal, and bulbar muscles with related deficits in activities of daily living. Some patients also experience mood, cognitive (e.g., frontotemporal dementia), or behavioral changes. Typically, the disease is fatal within 2-5 years of clinical onset, often as a result of respiratory failure. There is no cure for ALS and treatment options are limited. Riluzole has been shown to slow disease progression and prolong survival to a modest degree (e.g., by about 2-3 months); because of this possible benefit, experts recommend that the drug should be offered to patients with ALS. Other interventions (e.g., noninvasive ventilation, percutaneous gastrotomy [PEG]) also should be considered for symptomatic treatment of the disease. Management of ALS requires a multidisciplinary approach to address patients' physical deficits (e.g., loss of mobility, respiratory failure, dysarthria, dysphagia) as well as their social and psychological needs.

Clinical Experience

The current indication for riluzole is based principally on 2 double-blind, placebo-controlled studies in patients with familial or sporadic ALS (probable or definite) who had a disease duration of less than 5 years and a baseline forced vital capacity (FVC) of 60% or greater. In these studies, the time to death or insertion of a tracheostomy in patients receiving riluzole for at least 1 year (maximum of 18 months) was prolonged compared with that in placebo recipients.

In the first placebo-controlled study, survival benefit with riluzole therapy occurred principally in patients with bulbar- versus limb-onset ALS, possibly an artifact of the small sample size; site of disease onset did not influence survival benefit in the second, larger study. Differences in survival in both studies were observed early in treatment and diminished thereafter; mortality at the end of the studies was not significantly different between the treatment and placebo groups. In the first study in 155 patients, 57 of 77 patients (74%) receiving riluzole 100 mg daily (50 mg twice daily) were alive at 12 months compared with 45 of 78 patients (58%) receiving placebo. Survival benefit was attributable almost entirely to increased survival in patients with bulbar-onset ALS; 1-year survival rates with riluzole and placebo were 73 and 35%, respectively, in patients with bulbar-onset disease, compared with 74 and 64%, respectively, in patients with limb-onset disease. In the second placebo-controlled study in 959 patients, which included a dose-ranging evaluation, the probability of survival at the end of the study was greater in patients receiving riluzole 100 mg daily (50 mg twice daily) compared with those receiving placebo; survival was not substantially different between the 50-mg daily dosage and placebo, or between the 100- and 200-mg daily dosages. Median survival was prolonged by approximately 60-90 days with riluzole in these studies. Muscle strength and neurologic function did not improve with riluzole therapy in these studies, although in the first study a slower rate of deterioration in muscle strength was observed.

Dosage and Administration


Serum aminotransferase concentrations (e.g., ALT) should be monitored before initiation of riluzole and periodically during treatment.


Riluzole is administered orally twice daily. Because food decreases oral bioavailability of the drug, the manufacturer recommends that riluzole be taken in a fasting state (e.g., 1 hour before or 2 hours after meals).


For the management of amyotrophic lateral sclerosis (ALS), the recommended dosage of riluzole is 50 mg twice daily. Higher daily dosages have not been shown to provide any additional benefit but may increase the risk of adverse effects.

Special Populations

The manufacturer makes no specific recommendations for dosage adjustment in patients with hepatic impairment; however, use of riluzole is not recommended in patients with aminotransferase concentrations exceeding 5 times the upper limit of normal (ULN) or evidence of liver dysfunction.(See Hepatic Effects under Cautions: Warnings/Precautions.)



Riluzole is contraindicated in patients with a history of severe hypersensitivity reactions to the drug or any ingredient in the formulation.


Sensitivity Reactions

Hypersensitivity Reactions

Anaphylaxis has been reported in patients receiving riluzole.

Hepatic Effects

Liver injury, including fatalities, has been reported in patients receiving riluzole. Asymptomatic elevations of aminotransferase concentrations (e.g., ALT) also have been reported and have recurred following rechallenge with the drug in some patients. In clinical studies, the incidence of elevated aminotransferase concentrations was greater in patients receiving riluzole than in those receiving placebo; among riluzole-treated patients, approximately 50% had at least one elevated ALT concentration above the upper limit of normal (ULN) and 8% had ALT concentrations exceeding 3 times the ULN. Elevations in ALT concentrations exceeding 5 times the ULN were reported in 2% of patients receiving the drug. Maximum increases in ALT concentrations occurred within the first 3 months of therapy. Acute hepatitis and icteric toxic hepatitis have been reported during postmarketing experience with riluzole.

Serum aminotransferase concentrations should be monitored prior to and during riluzole therapy; in addition, patients should be monitored for signs and symptoms of hepatic injury (monthly for the first 3 months of treatment, then periodically thereafter). Use of riluzole is not recommended in patients with aminotransferase concentrations exceeding 5 times the ULN. The drug should be discontinued if there is evidence of liver dysfunction (e.g., elevated bilirubin concentrations).


Cases of severe neutropenia (absolute neutrophil count less than 500/mm) have been reported within the first 2 months of riluzole therapy. Patients should be advised to report febrile illness.

Interstitial Lung Disease

Interstitial lung disease, including hypersensitivity pneumonitis, has occurred in patients receiving riluzole. Riluzole should be discontinued immediately if interstitial lung disease develops.

Specific Populations


There are no adequate data to determine whether riluzole is associated with a risk of developmental abnormalities when used during pregnancy. In animal studies, administration of riluzole to pregnant rats and rabbits resulted in adverse developmental effects (e.g., decreased embryofetal/offspring viability, growth, and functional development) at clinically relevant doses.

If riluzole is used during pregnancy, the patient should be advised of the potential risk to the fetus.


It is not known whether riluzole is distributed into human milk. Riluzole or its metabolites have been detected in milk of lactating rats.

Patients should be advised that the potential for serious adverse effects in nursing infants from riluzole is not known.

Pediatric Use

Efficacy and safety of riluzole have not been established in pediatric patients.

Geriatric Use

No overall differences in safety and efficacy have been observed in geriatric patients 65 years of age or older compared with younger adults. Age does not appear to have a clinically important effect on the pharmacokinetics of riluzole. However, greater sensitivity in some older individuals cannot be ruled out.

Hepatic Impairment

In patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment, the area under the concentration-time curve (AUC) of riluzole increased by 1.7- or 3- fold, respectively, compared with individuals with normal hepatic function. Such patients may be at increased risk of adverse effects.

The pharmacokinetics of riluzole have not been studied in patients with severe hepatic impairment.

Use of riluzole is not recommended in patients with preexisting signs or symptoms of liver dysfunction.(See Hepatic Effects under Cautions: Warnings/Precautions.)

Renal Impairment

Moderate to severe renal impairment is not expected to have a clinically important effect on the pharmacokinetics of riluzole. The pharmacokinetics of riluzole have not been studied in patients undergoing hemodialysis.


The mean AUC of riluzole was approximately 45% higher in female patients compared with male patients. In clinical studies, dizziness was reported with higher frequency in females (11%) versus males (4%).


The clearance of riluzole was 50% lower in Japanese patients compared with Caucasian patients after normalizing for body weight. Based on this finding, Japanese patients may be more likely to have increased riluzole concentrations and risk of associated adverse effects.


The clearance of riluzole was approximately 20% higher in smokers compared with nonsmokers.

Common Adverse Effects

Adverse effects reported in 2% or more of patients receiving riluzole and more frequently than with placebo include asthenia, nausea, decreased lung function, hypertension, abdominal pain, vomiting, arthralgia, dizziness, dry mouth, insomnia, pruritus, tachycardia, flatulence, increased cough, peripheral edema, urinary tract infection, circumoral paresthesia, somnolence, vertigo, and eczema.

Drug Interactions

Drugs Affecting Hepatic Microsomal Enzymes

Riluzole is a substrate of cytochrome P-450 (CYP) 1A2. In vitro data suggest that increased riluzole exposure is likely if the drug is used concomitantly with CYP1A2 inhibitors. Concomitant use of riluzole with moderate or potent CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, vemurafenib, zileuton) may increase the risk of riluzole-associated adverse effects.

In vitro data suggest that decreased riluzole exposure is likely if the drug is used concomitantly with CYP1A2 inducers. Reduced riluzole exposure may result in decreased efficacy of the drug.

Hepatotoxic Drugs

Patients receiving potentially hepatotoxic drugs (e.g., allopurinol, methyldopa, sulfasalazine) were excluded from clinical studies of riluzole. Patients receiving riluzole concomitantly with hepatotoxic drugs may be at increased risk for hepatotoxicity.

Protein-bound Drugs

Protein-binding displacement interactions have not been observed with riluzole. In vitro studies indicate that riluzole binding to plasma proteins is not affected by warfarin, digoxin, imipramine, or quinine at high therapeutic concentrations.

In vitro, riluzole did not show displacement of warfarin from plasma proteins.

Write Your Own Review

Your meds on autopilot. Forever.